Clinical Trials Logo
  1. Home
  2. Other
  3. NCT04600947

Study of LP002 for the Treatment of Patients With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma

Primary Mediastinal Large B-Cell Lymphoma (PMBCL) Clinical Trial

Official title:
A Multicenter, Open-Label, Single-arm Phase II Study of LP002 in Subjects With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma

Clinical Trial Summary

LP002 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors. In this study, the efficacy and safety of LP002 for the treatment of relapsed or refractory primary mediastinal large B-cell lymphoma will be evaluated.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04600947
Study type Interventional
Source Taizhou HoudeAoke Biomedical Co., Ltd.
Contact Yuankai Shi, MD
Phone 010-87676061
Email syuankai@cicams.ac.cn
Status Not yet recruiting
Phase Phase 2
Start date December 30, 2020
Completion date May 30, 2023
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04526834 - Phase 1 Study of Autologous CD30.CAR-T in Relapsed or Refractory CD30 Positive Non-Hodgkin Lymphoma Phase 1
Recruiting NCT06339255 - Italian Observational Study on CAR-T Therapy for Lymphoma
Recruiting NCT06026319 - CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma Phase 1
Active, not recruiting NCT05162170 - Primary Mediastinal Large B-cell Lymphoma (PMBCL): Multicenter Retrospective Study
Recruiting NCT05934448 - Pembro Plus CAR T-cell Therapy in R/R in PMBCL Phase 2
Recruiting NCT04186520 - CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies Phase 1/Phase 2
Recruiting NCT04836507 - Study of Efficacy and Safety of CRC01 in Adult Large B-cell Lymphoma Patients Phase 1/Phase 2
Active, not recruiting NCT04875195 - A Study of Pembrolizumab (MK-3475) in Relapsed or Refractory Classical Hodgkin's Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) (MK-3475-B68) Phase 2
Active, not recruiting NCT03625037 - First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma Phase 1/Phase 2
Recruiting NCT06024694 - Primary Mediastinal Large B-cell Lymphoma With CNS Involvement
Not yet recruiting NCT06208735 - CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies Phase 1
Active, not recruiting NCT05856708 - CNS Involvement in Primary Mediastinal Large B-Cell Lymphoma (PMLBCL)
Completed NCT05130489 - CAR T Cell Therapy Related Cardiovascular Outcomes
Not yet recruiting NCT05934084 - Lifestyles Implemented-Survivorship Care Plan In Lymphoma Survivors N/A
Recruiting NCT04745559 - Optimizing Cellular and Humoral Immunity by Vaccinating With PCV13 Before and After CAR-T Therapy Phase 2
Recruiting NCT05366569 - Bio-CAR-T BS Study
Recruiting NCT06014762 - P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies Phase 1
Approved for marketing NCT05733650 - Expanded Access Program for Epcoritamab